# Clovis Oncology

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/clovis-oncology/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | company in Boulder, United States |
| OpenAlex ID | https://openalex.org/F4320315087 |
| ROR ID | https://ror.org/04ps4d441 |
| Works | 1,239 |

## Funder papers

- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)
- [Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study](https://scholariq.org/papers/rucaparib-maintenance-for-newly-diagnosed-advanced-ovarian-cancer-interim/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.